A construction company has lost its appeal of a ruling that it illegally blocked CFMMEU officials from entering a work site to meet with union members, with a judge saying the union did not need to prove intent to obstruct to make its case for violations of the Fair Work Act.
Spotless Services is challenging a ruling that it owes redundancy to three workers employed at the Perth International Airport that were on fixed contracts.
A former staffer to federal minister Michaelia Cash admitted in court Monday to alerting the media about federal police raids on the offices of the Australian Workers’ Union, but he refused to reveal who tipped him off.
Biotech company Cryosite has agreed to pay $1.05 million to settle the competition regulator’s landmark case alleging it jumped the gun on a proposed merger agreement with rival Cell Care.
A former Norton Rose Fulbright partner says he may file a contempt of court motion against the firm for allegedly failing to produce certain evidentiary documents for over two years.
Railway technology company Wavetrain Systems has asked the court to bar a competitor started by its former CEO from making allegedly false claims about its patented rail safety devices to clients.
AFT Pharmaceuticals has launched a partial challenge to a court ruling that its Maxigesic ads made a number of misleading claims, including that the drug provides stronger and more effective relief than Reckitt Benckiser’s Nuromol.
A judge that rejected a bid by Sanofi-Aventis for an injunction blocking rival Alphapharm from listing an insulin injector pen on the PBS erred in his consideration of the harm it would face, the drug giant has told the Full Federal Court.
Acciona Infrastructure and Transport for NSW are currently in settlement talks over a $1.2 billion dispute around the NSW government’s ongoing light rail project in Sydney.
Pharmaceutical giant Wyeth has shot down arguments by rival Merck Sharp & Dohme that its Prevnar 13 vaccine lacked inventiveness, saying during the closing submissions of a high-stakes patent trial that up until it developed the top-selling shot scientists thought there was a “ceiling” of 11 types of pneumococcal bacteria that could be included in a single vaccine.